Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489807 | 0.88 | TDP1 (0.44) | TP53ESR1NPC1JAK2RAB9A | |
| SCHEMBL704306 | 0.86 | NPC1 (0.47) | TP53ESR1NPC1JAK2RAB9A | |
| SCHEMBL707049 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL16415140 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL16414652 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL3458580 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL7651316 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL15352674 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL7914609 | 0.85 | NPC1 (0.50) | TP53ALDH1A1NPC1JAK2RAB9A | |
| SCHEMBL305841 | 0.83 | TSHR (0.47) | TP53DRD3ESR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0748219-B8 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 2005-06-08 | — | — | EP | claimed |
| EP-0748219-A4 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN INC (US) | 1999-06-16 | — | — | EP | claimed |
| EP-0748219-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | Sugen, Inc. (US) | 1996-12-18 | — | — | EP | claimed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | claimed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-10439252-B2 | Electrolyte solution for electrochemical device, and electrochemical device | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-10-08 | — | — | US | disclosed |
| US-9758513-B2 | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2017-09-12 | — | — | US | disclosed |
| US-9704612-B2 | Composition of silver-conjugated compound composite | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-07-11 | — | — | US | disclosed |
| CN-104271571-B | Tetrazolinone compound and use thereof | 住友化学株式会社 | 2017-07-07 | — | — | CN | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017061534-A1 | DIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2017-04-13 | — | — | WO | disclosed |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| EP-0696586-A1 | SERINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1996-02-14 | — | — | EP | disclosed |
| EP-0678511-A2 | Thiazolidine and oxazolidine derivatives, their preparation and their medical use | SANKYO COMPANY LIMITED (JP) | 1995-10-25 | — | — | EP | disclosed |
| WO-1995021613-A1 | COMPOUNDS FOR THE TREATMENT OF DISORDERS RELATED TO VASCULOGENESIS AND/OR ANGIOGENESIS | SUGEN, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| EP-0487071-B1 | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-07-05 | — | — | EP | disclosed |
| CN-1097417-A | New heterogeneous ring compound | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-01-18 | — | — | CN | disclosed |
| US-5273974-A | Condensed heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-28 | — | — | US | disclosed |
| EP-0487071-A1 | Condensed heterocyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-05-27 | — | — | EP | disclosed |
| US-4257995-A | STORAGE STABILITY | THE UPJOHN COMPANY (US) | 1981-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | TP53 2605/4885DRD3 1151/4885ESR1 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.